Haleon Hires Carl Haney to Lead R&D

Haleon, the consumer health company behind brands such as Advil, Centrum, Emergen-C, Theraflu and Gas-X, has appointed a new chief research and development officer. 

Carl Haney will step into the role in August, replacing Franck Riot, who is leaving the company after six years. 

Haney joins Haleon from Estée Lauder Cos., where he served as executive vice president of global innovation, research and development for the past 13 years. In that role, he focused on driving transformative product innovation across the end-to-end R&D network and worked closely with the global value chain organization to maximize quality and value within innovation, according to his LinkedIn profile. 

Also read: Last year, Haleon tapped a new executive to elevate customer strategy with analytics

Prior to that, he spent more than two decades at Procter & Gamble, working across several VP and R&D roles across its home, health and beauty care segments. Haney said on LinkedIn that he worked on consumer-inspired and idea-led technology through innovations across U.S., Latin America and Europe during his time at P&G.

Haleon CEO Brian McNamara said in a statement that Haney is a world-renowned leader in R&D, who brings experience in driving transformative innovation within global consumer businesses.